SK Biopharmaceuticals Future Growth
Future criteria checks 6/6
SK Biopharmaceuticals is forecast to grow earnings and revenue by 81.3% and 22.8% per annum respectively. EPS is expected to grow by 83.1% per annum. Return on equity is forecast to be 37.3% in 3 years.
Key information
81.3%
Earnings growth rate
83.1%
EPS growth rate
| Pharmaceuticals earnings growth | 34.5% |
| Revenue growth rate | 22.8% |
| Future return on equity | 37.3% |
| Analyst coverage | Good |
| Last updated | 16 Apr 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 806,599 | 186,877 | 102,000 | 132,000 | 7 |
| 12/31/2025 | 650,577 | 118,328 | 117,336 | 127,467 | 15 |
| 12/31/2024 | 484,975 | 31,690 | 35,530 | 48,609 | 13 |
| 12/31/2023 | 354,892 | -32,883 | -97,451 | -94,201 | N/A |
| 9/30/2023 | 290,903 | -83,502 | -124,549 | -119,901 | N/A |
| 6/30/2023 | 289,399 | -84,533 | -146,546 | -141,462 | N/A |
| 3/31/2023 | 265,819 | -106,594 | -157,666 | -151,460 | N/A |
| 12/31/2022 | 246,179 | -139,431 | -165,881 | -159,920 | N/A |
| 9/30/2022 | 414,148 | -48,445 | -194,822 | -188,994 | N/A |
| 6/30/2022 | 349,264 | -77,756 | -102,358 | -96,193 | N/A |
| 3/31/2022 | 319,801 | -99,351 | -118,776 | -113,474 | N/A |
| 12/31/2021 | 418,645 | 64,846 | -98,864 | -92,872 | N/A |
| 9/30/2021 | 203,992 | -40,396 | -38,937 | -30,581 | N/A |
| 6/30/2021 | 183,964 | -59,196 | -172,311 | -160,196 | N/A |
| 3/31/2021 | 162,060 | -51,828 | -197,006 | -181,777 | N/A |
| 12/31/2020 | 25,999 | -247,414 | -225,063 | -210,726 | N/A |
| 9/30/2020 | 10,115 | -242,367 | -284,100 | -270,297 | N/A |
| 6/30/2020 | 6,274 | -229,537 | -260,554 | -247,808 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A326030 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: A326030 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A326030 is expected to become profitable in the next 3 years.
Revenue vs Market: A326030's revenue (22.8% per year) is forecast to grow faster than the KR market (9.2% per year).
High Growth Revenue: A326030's revenue (22.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A326030's Return on Equity is forecast to be high in 3 years time (37.3%)